1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,505 | 0,530 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IMMUNEONCO-B (01541): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2026 | - | HKEx | ||
| Do | IMMUNEONCO-B (01541): NOTICE OF THE ANNUAL GENERAL MEETING | - | HKEx | ||
| Do | IMMUNEONCO-B (01541): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 ... | - | HKEx | ||
| Mi | IMMUNEONCO-B (01541): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 30.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY ... | - | HKEx | ||
| 25.03. | IMMUNEONCO-B (01541): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 13.03. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 06.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - (1) UNUSUAL PRICE MOVEMENTS; AND (2) APPROVAL OF IND APPLICATION OF IMM0306S (SUBCUTANEOUS FORMULATION) ... | - | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.02. | IMMUNEONCO-B (01541): CONNECTED TRANSACTION - THE LOAN AGREEMENT | 2 | HKEx | ||
| 21.01. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) | 3 | HKEx | ||
| 12.01. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS | - | HKEx | ||
| 06.01. | Instil Bio und ImmuneOnco lösen Lizenzvereinbarung auf | 11 | Investing.com Deutsch | ||
| 06.01. | Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco | 4 | FierceBiotech | ||
| 06.01. | IMMUNEONCO-B (01541): INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M | - | HKEx | ||
| 06.01. | Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco | 232 | GlobeNewswire (Europe) | DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue... ► Artikel lesen | |
| 03.12.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 5 | HKEx | ||
| 27.11.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE PHASE III CLINICAL STUDY PROTOCAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR ... | 1 | HKEx | ||
| 20.11.25 | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTIONS AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 1,790 | +1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| SAREPTA THERAPEUTICS | 17,960 | +0,90 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,152 | -0,86 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 57,10 | -3,87 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| TELIX PHARMACEUTICALS | 9,300 | -0,90 % | Telix Pharmaceuticals Limited: TLX101-Px (Pixlumi) MAA Accepted in Europe | MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,757 | -1,05 % | EQS-Media: Attraktive Chance-Risiko-Konstellation? Onco-Innovations gibt erfolgreiches Scale-up bekannt | EQS-Media / 29.04.2026 / 12:18 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gab unter Bezugnahme auf seine Pressemitteilung vom 21. April 2026... ► Artikel lesen | |
| TWIST BIOSCIENCE | 51,22 | +2,95 % | Twist Bioscience Q2 2026 Earnings Preview | ||
| REPLIGEN | 96,98 | -3,79 % | Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1 | ||
| UNIQURE | 16,640 | -2,12 % | uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease | ~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential... ► Artikel lesen | |
| PHARMAMAR | 96,45 | +0,36 % | PHARMA MAR, S.A.: The Company files first quarter 2026 financial information. |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,012 (-2,48 %) liegt der Kurs bei 0,472 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.